Corona Remedies

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE02ZQ01018
  • NSEID: CORONA
  • BSEID: 544644
INR
1,506.00
48.8 (3.35%)
BSENSE

Feb 03

BSE+NSE Vol: 75.02 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1,436.551,508.90

52 Week

0.000.00
Valuation
Technical
Day's Volume

CASH

75.02 k (77.43%) Volume

Shareholding (Dec 2025)

FII

1.84%

Held by 18 FIIs

DII

0.05%

Held by 10 DIIs

Promoter

69.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 8,786 Cr ()

stock-summary
P/E

60.00

stock-summary
Industry P/E

32

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.00

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

14.76

Revenue and Profits:
Net Sales:
342 Cr
(Quarterly Results - Dec 2025)
Net Profit:
41 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Icon
Company does not have enough history
Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary

Intimation Of Violation Under The Companys Code Of Conduct For Regulating Monitoring And Reporting Of Insider Trading In Securities And The SEBI (Prohibition Of Insider Trading) Regulations 2015

30-Jan-2026 | Source : BSE

Intimation of violation under the Companys Code of Conduct for Regulating Monitoring and Reporting of Insider Trading in securities and the SEBI (Prohibition of Insider Trading) Regulations 2015

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

28-Jan-2026 | Source : BSE

Intimation of Schedule of Analyst / Investor Call

Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of Unaudited Financial Results On Standalone And Consolidated Basis For The Third Quarter And Nine Months Ended On December 31 2025

27-Jan-2026 | Source : BSE

Corona Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2026 inter alia to consider and approve Board Meeting intimation for consideration and approval of Unaudited Financial Results on Standalone and Consolidated basis for the third quarter and nine months ended on December 31 2025

Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
19.13
Debt to EBITDA (avg)
0.38
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.86
Tax Ratio
24.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.60%
ROCE (avg)
29.97%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
60
Industry P/E
32
Price to Book Value
14.76
EV to EBIT
44.05
EV to EBITDA
37.23
EV to Capital Employed
14.91
EV to Sales
7.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
33.85%
ROE (Latest)
24.61%
Technicals key factors
Indicator
Weekly
Monthly
Icon
No records
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 13 Schemes (6.38%)

FIIs

Held by 18 FIIs (1.84%)

Promoter with highest holding

Ankurbhai K Mehta (22.0%)

Highest Public shareholder

Sepia Investments Limited (19.76%)

Individual Investors Holdings

1.36%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -5.18% vs 4.21% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -20.90% vs 12.39% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "342.42",
          "val2": "361.13",
          "chgp": "-5.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "83.16",
          "val2": "78.47",
          "chgp": "5.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.66",
          "val2": "1.93",
          "chgp": "-13.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "41.25",
          "val2": "52.15",
          "chgp": "-20.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "24.29%",
          "val2": "21.73%",
          "chgp": "2.56%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Corona Remedies"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Corona Remedies"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,196.42",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "239.98",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "10.60",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "149.05",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.06%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary
Dec'25
Sep'25
Change(%)
Net Sales
342.42
361.13
-5.18%
Operating Profit (PBDIT) excl Other Income
83.16
78.47
5.98%
Interest
1.66
1.93
-13.99%
Exceptional Items
-19.10
0.00
Standalone Net Profit
41.25
52.15
-20.90%
Operating Profit Margin (Excl OI)
24.29%
21.73%
2.56%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -5.18% vs 4.21% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -20.90% vs 12.39% in Sep 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Change(%)
Net Sales
1,196.42
NA
NA
Operating Profit (PBDIT) excl Other Income
239.98
NA
NA
Interest
10.60
NA
NA
Exceptional Items
0.00
NA
NA
Standalone Net Profit
149.05
NA
NA
Operating Profit Margin (Excl OI)
20.06%
NA%
NA
Values in Rs Cr.
stock-summary Compare with Peers
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Resultsstock-summary
stock-summaryCompany CV
About stock-summary
stock-summary
Company Coordinates stock-summary
Company Details
stock-summary
Tel:
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support@mojoinfinity.com, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."